Bell, K. J. L., Boroumand, F., Wu, Z., Wilt, T. J., Parker, L., Millar, J., Smith, J., McCaffery, K., Brodersen, J. B., Dahm, P., Delahunt, B., Glasziou, P., Warden, A., Diller, L., van Rensburg, C., & Nickel, B. (2026). Impact of diagnostic labels and management benefit-to-harms information for low-risk prostate pathology. Journal of the National Cancer Institute, djag248. Advance online publication. https://doi.org/10.1093/jnci/djag248
Impact of diagnostic labels and management benefit-to-harms information for low-risk prostate pathology
Previous
Previous
Mind the Gap: Impact of New Labels on Public Perceptions and Calculated Risk of Adverse Outcomes after a Melanoma In Situ Diagnosis-A Secondary Analysis of an Online Randomized Experiment
Next
Next